{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:16:33Z","timestamp":1780575393918,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01125-4","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:55:10Z","timestamp":1780574110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical recurrence after radical prostatectomy: Where do we stand to?"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-6429","authenticated-orcid":false,"given":"Rolando Maria","family":"D\u2019Angelillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Eolo","family":"Trodella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edy","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591\u20137.","journal-title":"JAMA"},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.juro.2006.03.093","volume":"176","author":"BS Carver","year":"2006","unstructured":"Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical T3 prostate cancer. J Urol. 2006;176:564\u20138.","journal-title":"J Urol"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","volume":"165","author":"CL Amling","year":"2001","unstructured":"Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate-specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol. 2001;165:1146\u201351.","journal-title":"J Urol"},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.juro.2015.12.075","volume":"195","author":"A Toussi","year":"2016","unstructured":"Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, et al. Standardizing the definition of biochemical recurrence after radical prostatectomy: what prostate-specific antigen cut point best predicts a durable increase and subsequent systemic progression?. J Urol. 2016;195:1754\u20139.","journal-title":"J Urol"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2016.10.026","volume":"121","author":"CR King","year":"2016","unstructured":"King CR. The dose\u2013response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol. 2016;121:199\u2013203.","journal-title":"Radiother Oncol"},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926\u201337.","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"1125_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.2024.42.4_suppl.119","volume":"42","author":"BA Hadaschik","year":"2024","unstructured":"Hadaschik BA, Mottet N, Ost P, De Nunzio C, Tunariu N, Zaucha R, et al. Baseline characteristics of patients with PSMA-PET\u2013positive and \u2013negative disease with high risk of biochemical recurrence after radical prostatectomy in the ongoing phase 3 PRIMORDIUM study. J Clin Oncol. 2024;42(Suppl 4):119.","journal-title":"J Clin Oncol"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2025.3746","volume":"11","author":"C Belliveau","year":"2025","unstructured":"Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Taussky D, et al. Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized clinical trial. JAMA Oncol. 2025;11:1431\u20138.","journal-title":"JAMA Oncol"},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025;26:695\u2013706.","journal-title":"Lancet Oncol"},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901.","journal-title":"Lancet"},{"key":"1125_CR11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3 randomised trial. Lancet Oncol. 2019;20:1740\u20139.","journal-title":"Lancet Oncol"},{"key":"1125_CR12","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, et al. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. Lancet. 2024;403:2405\u201315.","journal-title":"Lancet"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024;403:2416\u201325.","journal-title":"Lancet"},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(26)00137-6","volume":"407","author":"AU Kishan","year":"2026","unstructured":"Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, et al. Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026;407:1059\u201371.","journal-title":"Lancet"},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.eururo.2025.05.013","volume":"88","author":"S Burdett","year":"2025","unstructured":"Burdett S, Fisher DJ, Tierney JF, Cook AD, Spratt DE, Dignam JJ, et al. DADSPORT Meta-analysis Collaboration. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol. 2025;88:277\u201390.","journal-title":"Eur Urol"},{"key":"1125_CR16","unstructured":"European Association of Urology. EAU guidelines on prostate cancer. Available at: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment (accessed March 13, 2026)."},{"key":"1125_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27:192\u2013201.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1125_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41391-018-0112-3","volume":"22","author":"D Bottke","year":"2019","unstructured":"Bottke D, Bartkowiak D, Siegmann A, Thamm R, B\u00f6hmer D, Budach V, et al. Effect of early salvage radiotherapy at PSA\u2009<\u20090.5\u2009ng\/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:344\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1125_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41391-024-00878-0","volume":"28","author":"V Achard","year":"2025","unstructured":"Achard V, Zilli T. Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting. Prostate Cancer Prostatic Dis. 2025;28:737\u201342.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41391-024-00890-4","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Fazekas T, Miszczyk M, Tsuboi I, Kardoust Parizi M, et al. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28:610\u201322.","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01125-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:55:13Z","timestamp":1780574113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01125-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":20,"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01125-4","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}